NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 26 May 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Peter Jackson (Chair Topic 1) Items 1 to 4.2.2
2. Dr Megan John (Chair Topics 2, 3 & 4) Present for all items
3. Dr Lindsay Smith (Vice Chair) Items 1 to 4.1.3 & 5 to 6.2.2
4. Dr Matthew Bradley Items 1 to 5.1.4
5. Professor Sofia Dias Present for all items
6. Chris Herring Present for all items
7. Dr Robert Hodgson Present for all items
8. Dr Bernard Khoo Present for all items
9. Ivan Koychev Items 1 to 6.2.2
10. Dr Soo Fon Lim Items 1 to 6.2.2
11. Dr Guy Makin Present for all items
12. Professor David Meads Items 1 to 6.2.2
13. Giles Monnickendam Present for all items
14. Dr Malcolm Oswald Items 1 to 6.2.2
15. Professor Chris Parker Items 1 to 4.2.2
16. Dr Rebecca Payne Present for all items
17. Carole Pitkeathley Items 1 to 5.1.4
18. Professor John Watkins Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Linda Landells, Associate Director Items 5 to 5.1.4

Celia Mayers, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Kate Moore, Project Manager Items 5 to 5.1.4

Victoria Kelly, Heath Technology Assessment Adviser Items 1 to 6.2.2

Hannah Nicholas, Heath Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 6 to 6.2.2

Alan Moore, Heath Technology Assessment Analyst Items 1 to 4.2.2

Tom Jarett, Heath Technology Assessment Analyst Items 1 to 4.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 5 to 5.1.4

Sarah Wilkes, Heath Technology Assessment Analyst Items 6 to 6.2.2

Haider Shamsi, Heath Technology Assessment Analyst Items 6 to 6.2.2

Anuja Chatterjee, Heath Technology Assessment Analyst Items 6 to 6.1.3

Owen Harrison, Heath Technology Assessment Analyst Items 1 to 4.2.2 & 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 4.2.2 & 6 to 6.1.3

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Items 1 to 5.1.4

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Items 1 to 5.1.4

Ruth Melville, Senior Medical Editor Items 1 to 5.1.4

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.2.2

Catherine Pank, Assistant Project Manager, COT Present for all items

Lucinda Evans, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Items 1 to 4.2.2

Laura Kelly, Administrator, TA Items 1 to 4.2.2

Mohammed Towhasir, Administrator, TA Items 5 to 5.1.4

Rumana Zaman, Administrator, TA Items 6 to 6.2.2

External assessment group representatives present

Andrew Metry, School of Health, and Related Research (ScHARR), Items 1 to 4.1.3

Matt Stevenson, School of Health, and Related Research (ScHARR), Items 1 to 4.1.3 & 6 to 6.1.3

Emma Simpson, School of Health, and Related Research (ScHARR), Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor James Catto, NIHR Research Professor and Professor of urology, Clinical expert nominated by BMS, Items 1 to 4.1.3 – Professor Catto was unable to stay for the duration of the presentation due to clinical responsibilities, but this was noted by the Chair at the start of the meeting. The Chair paused during the presentation to allow Professor Catto to provide his input and respond to questions from the appraisal committee.

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.2.2

Kevin Gorman, Patient expert nominated by Action Bladder Cancer UK, Items 1 to 4.1.3

Prof. Syed Hussain, Professor of Medical Oncology & Honorary Consultant, Clinical expert nominated by BMS, Items 1 to 4.1.3

Dr Lydia Makaroff, Patient expert nominated by Fight Bladder Cancer UK, Items 1 to 4.1.3

Dr Jan Dudley, Consultant Paediatric Nephrologist, Clinical expert nominated by Renal Association, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Peter Jackson welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 5 May 2022

### Appraisal of nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from BMS.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor James Catto declared direct financial interests as he has received funding from BMS for advisory boards and to run a half day teaching course for BMS staff. It was agreed that his declaration would not prevent Professor Catto from providing expert advice to the committee.
* Nominated patient expert Kevin Gorman declared indirect financial interests as Action Bladder Cancer UK received donations of £16,000 during the last 12 months from Bristol-Myers Squibb. It was agreed that his declaration would not prevent Kevin from providing expert advice to the committee.
* Nominated clinical expert Professor Syed Hussain declared direct financial interests as he has received advisory board/consultancy fees from: Roche, MSD, AstraZeneca, BMS, Janssen, Astellas, Bayer, Pierre Fabre, Sotio, GSK, Ipsen, Eisai, and research funding from: CR UK, MRC/NIHR, UHB charities, CCC charities, North West Cancer Research, Yorkshire Cancer research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly. It was agreed that his declaration would not prevent Professor Hussain from providing expert advice to the committee.
* Nominated patient expert Dr Lydia Makaroff declared indirect financial interests as Fight Bladder Cancer has received financial support from Roche, AstraZeneca, Arquer, Bayer, Astellas, Bristol-Myers Squibb, Ferring, Ipsen, Janssen, Merck, MSD, Olympus, Pfizer, Photocure, Prokarium, Sanofi, and SeaGen., World Bladder Cancer Patient Coalition has received financial support Roche, AstraZeneca, Bayer, Astellas, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, Photocure, and SeaGen. It was agreed that her declaration would not prevent Dr Makaroff from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Giles Monnickendam, Dr Rebecca Payne, and Carole Pitkeathley.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10742>

### Appraisal of guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID4013]

* 1. Part 2 – closed session - The nature of the discussion for this topic is commercially sensitive and will take place in a confidential part 2 discussions only.
		1. The chair Dr Megan John asked all committee members and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from Janssen, Celgene, Sanofi and Abbvie for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions of this appraisal.
* Committee member Dr Ivan Koychev declared non-financial professional interests as he is in existing collaboration with JnJ in the Alzheimer's disease space, part of which JnJ are to provide free AD biomarker testing on plasma samples they collect as part of a University of Oxford sponsored study. It was agreed that his declaration would not prevent Dr Koychev from participating in discussions of this appraisal.
* Committee member Professor Sofia Dias declared non-financial professional interests as she is part of the York EAG who carried out the original assessment of this appraisal but was not directly involved, she confirmed she was not involved with the Rapid Review. It was agreed that her declaration would not prevent Professor Dias from participating in discussions of this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the evidence presented to the committee.
		2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/ta711>

### Appraisal of slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

* 1. Part 1 – Open session
		1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Advicenne.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from Sanofi for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions of this appraisal.
* Committee member Dr Matthew Bradley declared financial interests as he is an employee of GSK, a stated comparator manufacturer.it was agreed that his declaration would prevent Dr Bradley from participating in discussions on this appraisal.
* Nominated clinical expert Dr Jan Dudley declared indirect interests as The Renal Association received sponsorship (£500) from Advicenne for the BAPN winter meeting. It was agreed that her declaration would not prevent Dr Dudley from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Bernard Khoo, Malcolm Oswald, and Sarah Wilkes (Technical Lead for this topic). Sarah presented the cost issues as the other lead team member was unwell and unable to attend the meeting.
	1. Part 2 – Closed session (company representatives, the clinical expert, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10753>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 7 July 2022 and will start promptly at 09.30.